EXCHANGE OF VIEWS | The future of Minnesota: How to contain health care costs, revisited

Opinion Editor’s Note: Star Tribune Opinion publishes a mix of national and local comments online and in print every day. (To contribute, click Here.) This article is a response to the June 4 Star Tribune opinion call for proposals on the question, “Where does Minnesota go from here?” Read the complete collection of answers Here. … Read more

After Yusimry’s discount, future prices for Adalimumab are unclear

Adalimumab, sold under the brand name Humira, has long been one of the best-selling drugs in the world. But its 20-year period without competition has ended, and despite its best efforts to delay its arrival, drugmaker AbbVie now faces increasing competition from biosimilars entering the market. But a biosimilar about to be launched could be … Read more